Live Breaking News & Updates on Brightstar study

Stay updated with breaking news from Brightstar study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

BRIGHTSTAR: Local Consolidative Therapy with Brigatinib in Tyrosine Kinase Inhibitor-Naïve ALK-Rearranged Metastatic NSCLC

Expert oncologist Yasir Elamin, MD, shares data from the BRIGHTSTAR trial and considers how it may inform real-world use of brigatinib in patient with ALK-rearranged metastatic non–small cell lung cancer. ....

Yasir-elamin , Local-consolidative-therapy , Tyrosine-kinase-inhibitor-na , Rearranged-metastatic , Nsclc , Non-small-cell-lung-cancer , Lung-cancer , Metastatic-nsclc , Metastatic-lung-cancer , Brightstar-trial , Brightstar-study